Skip to main content

Table 2 Results of subgroup analysis of pooled hazard ratios of OS of patients with different SII

From: Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Stratified analysis No. of studies Pooled HR (95% CI) P‐value Heterogeneity
I2 (%) PQ
Cancer type
RCC 7 2.73 (1.28, 5.81) 0.009 99 < 0.001
PC 3 2.29 (1.44, 3.63) < 0.001 46 0.160
BC 2 3.01 (1.35, 6.68) 0.007 0 0.870
Unclear 2 1.92 (1.46, 2.54) < 0.001 0 0.660
Urothelial cancer 4 2.03 (1.55, 2.63) < 0.001 0 0.730
Non urothelial cancer 10 2.67 (1.46, 4.88) 0.001 98 < 0.001
Study type
Prospective 1 2.99 (2.07, 4.32) < 0.001 NA NA
Retrospective 13 2.55 (1.53, 4.27) < 0.001 97 < 0.001
Treatment      
Surgery 5 1.70 (1.04, 2.79) 0.030 76 0.002
Non surgery 7 2.16 (1.74, 2.68) < 0.001 52 0.050
Mix 2 6.67 (1.40, 31.84) 0.020 98 < 0.001
Cut-off value
 0–500 2 9.05 (2.99, 27.41) < 0.001 82 0.020
 501–1000 9 1.84 (1.30, 2.59) < 0.001 90 < 0.001
 >1000 2 3.23 (2.38, 4.39) < 0.001 0 0.450
Analysis
 Multivariate 10 2.06 (1.44, 2.94) < 0.001 9.1 < 0.001
 Univariate 1 2.36 (1.78, 3.13) < 0.001 NA NA
  1. CI: confidence interval; HR: hazard ratio; OS: overall survival; SII: systemic immune‐inflammation index